CL2024000370A1 - Composiciones y métodos para el tratamiento de cáncer. - Google Patents
Composiciones y métodos para el tratamiento de cáncer.Info
- Publication number
- CL2024000370A1 CL2024000370A1 CL2024000370A CL2024000370A CL2024000370A1 CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1 CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- treatment
- cancer
- methods
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91097—Hexosyltransferases (general) (2.4.1)
- G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231694P | 2021-08-10 | 2021-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000370A1 true CL2024000370A1 (es) | 2024-10-25 |
Family
ID=85201061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000370A CL2024000370A1 (es) | 2021-08-10 | 2024-02-06 | Composiciones y métodos para el tratamiento de cáncer. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240360247A1 (https=) |
| EP (1) | EP4384220A4 (https=) |
| JP (1) | JP2024533998A (https=) |
| CN (1) | CN118139642A (https=) |
| AU (1) | AU2022326557A1 (https=) |
| CA (1) | CA3225489A1 (https=) |
| CL (1) | CL2024000370A1 (https=) |
| CO (1) | CO2024001405A2 (https=) |
| WO (1) | WO2023019186A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025171394A1 (en) * | 2024-02-09 | 2025-08-14 | The Johns Hopkins University | Compositions and methods for treatment of cancer |
| CN119861198B (zh) * | 2025-01-02 | 2025-09-16 | 哈尔滨脉图精准技术有限公司 | 用于区分早期肺癌与肺炎的血浆代谢标志物组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070085232A (ko) * | 2004-08-20 | 2007-08-27 | 더 존스 홉킨스 유니버시티 | 혈관신생 치료방법 |
| US11339213B2 (en) * | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| PE20181326A1 (es) * | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| US20200181264A1 (en) * | 2017-08-11 | 2020-06-11 | City Of Hope | Bispecific antigen-binding molecule |
| WO2019236722A1 (en) * | 2018-06-05 | 2019-12-12 | Chatterjee Subroto B | Inhibitors of glycosphingolipid synthesis and methods of use |
-
2022
- 2022-08-10 EP EP22856800.2A patent/EP4384220A4/en active Pending
- 2022-08-10 CA CA3225489A patent/CA3225489A1/en active Pending
- 2022-08-10 WO PCT/US2022/074785 patent/WO2023019186A2/en not_active Ceased
- 2022-08-10 CN CN202280068476.1A patent/CN118139642A/zh active Pending
- 2022-08-10 AU AU2022326557A patent/AU2022326557A1/en active Pending
- 2022-08-10 JP JP2024508333A patent/JP2024533998A/ja active Pending
-
2024
- 2024-02-06 CL CL2024000370A patent/CL2024000370A1/es unknown
- 2024-02-09 US US18/438,286 patent/US20240360247A1/en active Pending
- 2024-02-09 CO CONC2024/0001405A patent/CO2024001405A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384220A4 (en) | 2025-06-18 |
| JP2024533998A (ja) | 2024-09-18 |
| AU2022326557A1 (en) | 2024-01-25 |
| CA3225489A1 (en) | 2023-02-16 |
| CO2024001405A2 (es) | 2024-07-29 |
| WO2023019186A3 (en) | 2023-08-03 |
| US20240360247A1 (en) | 2024-10-31 |
| WO2023019186A2 (en) | 2023-02-16 |
| EP4384220A2 (en) | 2024-06-19 |
| CN118139642A (zh) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| NZ784224A (en) | Parp1 inhibitors | |
| PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
| CL2024000370A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| GEAP202115183A (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| PH12017502002A1 (en) | 5`-substituted nucleoside analogs | |
| MX389683B (es) | Composiciones terapeuticas, combinaciones y metodos de uso | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| MX374946B (es) | Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer. | |
| BR112019011199A2 (pt) | método para tratar um indivíduo que tem um câncer de próstata e kits | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2022007626A (es) | Combinaciones. | |
| CL2024001535A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |